![]() ![]() now owns 6,371 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 5,344 shares in the last quarter. grew its holdings in Fate Therapeutics by 520.4% during the fourth quarter. bought a new stake in Fate Therapeutics during the fourth quarter worth $42,000. now owns 3,082 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 2,482 shares in the last quarter. grew its holdings in Fate Therapeutics by 413.7% during the fourth quarter. National Bank of Canada FI bought a new stake in Fate Therapeutics during the second quarter worth $25,000. Several institutional investors have recently bought and sold shares of FATE. Institutional Investors Weigh In On Fate Therapeutics 17.34% of the stock is owned by company insiders. Insiders have sold 75,708 shares of company stock valued at $396,710 over the last ninety days. The disclosure for this sale can be found here. Following the sale, the insider now owns 168,917 shares of the company’s stock, valued at approximately $885,125.08. The stock was sold at an average price of $5.24, for a total value of $57,205.08. Also, insider Bahram Valamehr sold 10,917 shares of the company’s stock in a transaction on Tuesday, January 10th. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Following the completion of the acquisition, the director now owns 246,139 shares of the company’s stock, valued at approximately $1,395,608.13. The stock was acquired at an average price of $5.67 per share, for a total transaction of $499,232.16. In related news, Director John Mendlein purchased 88,048 shares of the firm’s stock in a transaction that occurred on Wednesday, January 11th. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Following the transaction, the insider now directly owns 168,917 shares of the company’s stock, valued at $885,125.08. The stock was sold at an average price of $5.24, for a total transaction of $57,205.08. In other news, insider Bahram Valamehr sold 10,917 shares of the company’s stock in a transaction that occurred on Tuesday, January 10th. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $29.75. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and six have given a buy rating to the stock. They set a “buy” rating and a $16.00 price target for the company. I began coverage on Fate Therapeutics in a report on Thursday, January 5th. Cowen downgraded Fate Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, January 6th. BMO Capital Markets downgraded Fate Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $20.00 to $7.00 in a report on Friday, January 6th. SVB Leerink decreased their price objective on Fate Therapeutics from $62.00 to $10.00 and set an “outperform” rating for the company in a report on Friday, January 6th. ![]() Truist Financial restated a “hold” rating and issued a $7.00 price objective (down from $46.00) on shares of Fate Therapeutics in a report on Friday, January 6th. Wall Street Analysts Forecast GrowthĪ number of research firms recently weighed in on FATE. The stock had previously closed at $6.14. ![]() ![]() 1,021,788 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 4,487,517 shares. The company traded as high as $6.47 and last traded at $6.42. ( NASDAQ:FATE – Get Rating) shot up 4.6% on Friday. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |